Search Within

Vicky Makker

Formats
  1. Meeting Abstract (143)
  2. Journal Article (111)
  3. Review (9)
  4. Editorial (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (269)
  2. GDMT, Medicine (269)
  3. Gynecologic Medicine Service (269)
  4. Gynecology Disease Management Team (269)
  5. Solid Tumor Oncology Division (269)
  6. Surgery (94)

More Groups

People
  1. Carol Aghajanian (91)
  2. Nadeem Abu-Rustum (77)
  3. Mario Leitao (49)
  4. Alexia Iasonos (47)
  5. Kaled Alektiar (45)
  6. Qin Zhou (43)

More People

Years
  1. 2025 (13)
  2. 2024 (35)
  3. 2023 (39)
  4. 2022 (36)
  5. 2021 (19)
  6. 2020 (26)

More Years

Publications
  1. Gynecologic Oncology (65)
  2. Journal of Clinical Oncology (58)
  3. International Journal of Gynecological Cancer (38)
  4. Annals of Oncology (23)
  5. Gynecologic Oncology Reports (8)
  6. Clinical Cancer Research (6)

More Publications

Publishers
  1. Elsevier B.V. (73)
  2. American Society of Clinical Oncology (61)
  3. Lippincott Williams & Wilkins (39)
  4. Oxford University Press (26)
  5. American Association for Cancer Research (12)
  6. Elsevier Inc. (9)

More Publishers

Results (269)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Surgical cytoreduction in advanced stage serous endometrial carcinoma
    Meeting Abstract

    Pedra Nobre, S.; Zhou, Q.; Iasonos, A.; Chi, D.; Makker, V.; Abu-Rustum, N.; Leitao, M.; Mueller, J.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo Marin, M.; Bratos Lorenzo, R.; Brose, M. S.; DiSimone, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
    Meeting Abstract

    Moukarzel, L. A.; Stylianou, A.; Wu, M.; Nobre, S. P.; Abu-Rustum, N. R.; Broach, V.; Giri, D. D.; Iyengar, N. M.; Weigelt, B.; Makker, V.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
    Meeting Abstract

    Marth, C.; Vulsteke, C.; Rubio, M. J.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Radoslaw, M.; Ayhan, A.; Hasegawa, K.; Wu, X.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer
    Meeting Abstract

    Makker, V.; Herraez, A. C.; Aghajanian, C.; Fujiwara, K.; Pignata, S.; Penson, R. T.; Dutcus, C. E.; Guo, M.; Dutta, L.; Orlowski, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade, and serous endometrial cancers
    Meeting Abstract

    Broach, V.; Iyengar, N. M.; Zhou, X. K.; Wang, H.; Giri, D. D.; Williams, S.; Abu-Rustum, N.; Rubinstein, M. M.; Dannenberg, A. J.; Makker, V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
    Journal Article

    Tao, J. J.; Cangemi, N. A.; Makker, V.; Cadoo, K. A.; Liu, J. F.; Rasco, D. W.; Navarro, W. H.; Haqq, C. M.; Hyman, D. M.
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save